EMERYVILLE, Calif., Nov 19, 2024
Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced that, following the completion of a strategic review of its global R&D operations and business model, the company has made the decision to consolidate its R&D footprint in the U.S. and Brazil and cease funding its Portuguese subsidiary, Amyris Bio Products Portugal Unipessoal (ABP), whose area of focus – studying fermentation byproducts and waste – is no longer core to the Company’s business. As a result, ABP will file for insolvency effective immediately.
“Since emerging from Chapter 11 on May 7, 2024, Amyris has continued to evaluate its business model to optimize resource allocation and focus our R&D operations in the U.S. and Brazil,” said Kathy Fortmann, Amyris’ Chief Executive Officer. “This difficult yet necessary decision in no way reflects the dedication, talent and contributions of our Portugal employees over the years, for which we are grateful.”
About Amyris
Amyris is a vertically integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. Leveraging two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in thousands of products from the world’s top brands, reaching millions of consumers. For more information, please visit http://www.amyris.com.
Amyris Media Contact:
Corporate Communications
Email: [email protected]
Website: https://amyris.com/